JP2010520280A - ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御 - Google Patents

ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御 Download PDF

Info

Publication number
JP2010520280A
JP2010520280A JP2009552676A JP2009552676A JP2010520280A JP 2010520280 A JP2010520280 A JP 2010520280A JP 2009552676 A JP2009552676 A JP 2009552676A JP 2009552676 A JP2009552676 A JP 2009552676A JP 2010520280 A JP2010520280 A JP 2010520280A
Authority
JP
Japan
Prior art keywords
seq
notch1
notch2
cancer
numb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009552676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520280A5 (enExample
Inventor
コンスタンティン ジー． イオアニデス，
レイマンド エフ． エイク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2010520280A publication Critical patent/JP2010520280A/ja
Publication of JP2010520280A5 publication Critical patent/JP2010520280A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009552676A 2007-03-05 2008-02-08 ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御 Withdrawn JP2010520280A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90499407P 2007-03-05 2007-03-05
US96104607P 2007-07-18 2007-07-18
US95994607P 2007-07-18 2007-07-18
US95997107P 2007-07-18 2007-07-18
PCT/US2008/001694 WO2008108910A2 (en) 2007-03-05 2008-02-08 Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy

Publications (2)

Publication Number Publication Date
JP2010520280A true JP2010520280A (ja) 2010-06-10
JP2010520280A5 JP2010520280A5 (enExample) 2012-04-12

Family

ID=39539638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552676A Withdrawn JP2010520280A (ja) 2007-03-05 2008-02-08 ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御

Country Status (4)

Country Link
US (1) US20100062012A1 (enExample)
EP (1) EP2134356A2 (enExample)
JP (1) JP2010520280A (enExample)
WO (1) WO2008108910A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101535219B1 (ko) * 2011-11-18 2015-07-09 한국생명공학연구원 Ｎｏｔｃｈ３에 대한 인간 단일클론항체

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
BRPI0914007A2 (pt) 2008-07-08 2015-11-17 Oncomed Pharm Inc anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
AU2010261364B2 (en) 2009-06-18 2015-05-07 Pfizer Inc. Anti Notch-1 antibodies
AU2010300747A1 (en) * 2009-09-30 2012-04-26 Genentech, Inc. Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
CN109467598B (zh) * 2018-11-28 2021-11-09 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057621A1 (en) * 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
CA2546017A1 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101535219B1 (ko) * 2011-11-18 2015-07-09 한국생명공학연구원 Ｎｏｔｃｈ３에 대한 인간 단일클론항체

Also Published As

Publication number Publication date
WO2008108910A3 (en) 2008-11-20
US20100062012A1 (en) 2010-03-11
EP2134356A2 (en) 2009-12-23
WO2008108910A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
JP2010520280A (ja) ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
JP7034505B2 (ja) 消化管癌および胃癌を含む数種の腫瘍に対する新規免疫療法
CN110787285B (zh) Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法
TWI711633B (zh) 腫瘤抗原胜肽
Kajiwara et al. Hypoxia augments MHC class I antigen presentation via facilitation of ERO1‐α‐mediated oxidative folding in murine tumor cells
US8975371B2 (en) Melanoma antigen peptide and uses thereof
JP4365405B2 (ja) Ｍｈｃ分子と結合する腫瘍関連ペプチド
UA110119C2 (xx) Пептиди tomm34 та вакцини, що їх містять
Coulie et al. Characterization of Antigens Recognized by T Cells on Human Tumors
WO2019160099A1 (ja) がん抗原ペプチド
Van Pel et al. CHARACTERIZATION OF ANTIGENS RECOGNIZED BY T CELLS ON HUMAN
Dadvar Characterization of cancer/testis antigen MAGE-A11 for immunotherapy of prostate cancer
Han Functional characterization of FMNL1 as potential target for novel anti-tumor therapies
HK40022679A (en) Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120611

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120703